Paper42518232
Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review.
Xiao H and 6 others. JAMA Netw Open, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review. Papers, record 42518232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42518232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Trials as Topic | Major topic |
| Neoplasms | Major topic |
| Drug Costs | Major topic |
| Antineoplastic Agents | Major topic |
| Financing, Government | Major topic |
| Humans | |
| United States |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| UG1 CA189974 | NCI NIH HHS | United States | UG1CA189974 | PubMed |
Source NIH RePORTER
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39331856 | Bridging the Gap in Cancer Clinical Trial Funding. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39331856 | PubMed |
| 2 | 17008693 | Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/17008693 | PubMed |
| 3 | 31533793 | Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. | Trials | 2019 | https://conductscience.org/library/papers/31533793 | PubMed |
| 4 | 39331494 | Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39331494 | PubMed |
| 5 | 23363807 | Publicly funded clinical trials and the future of cancer care. | Oncologist | 2013 | https://conductscience.org/library/papers/23363807 | PubMed |
| 6 | 28679092 | Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28679092 | PubMed |
| 7 | 31483471 | Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. | JAMA Netw Open | 2019 | https://conductscience.org/library/papers/31483471 | PubMed |
| 8 | 32970346 | What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. | Cancer | 2020 | https://conductscience.org/library/papers/32970346 | PubMed |
| 9 | 36848615 | The National Clinical Trials Network: A Valuable and Undervalued Resource. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36848615 | PubMed |
| 10 | 36218748 | Estimating Rebates and Other Discounts Received by Medicare Part D. | JAMA Health Forum | 2021 | https://conductscience.org/library/papers/36218748 | PubMed |
| 11 | 31845965 | Evolution of Cancer Care Delivery Research in the NCI Community Oncology Research Program. | J Natl Cancer Inst | 2020 | https://conductscience.org/library/papers/31845965 | PubMed |
| 12 | 40658397 | Oncology "Me-Too" Drugs Compared With Original Drugs in Randomized Clinical Trials. | JAMA Intern Med | 2025 | https://conductscience.org/library/papers/40658397 | PubMed |
| 13 | 33793310 | Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example. | Am Soc Clin Oncol Educ Book | 2021 | https://conductscience.org/library/papers/33793310 | PubMed |
| 14 | 29440428 | Contribution of NIH funding to new drug approvals 2010-2016. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29440428 | PubMed |
| 15 | 34196656 | Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/34196656 | PubMed |
| 16 | 28968170 | Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28968170 | PubMed |
| 17 | 37815344 | Insurance Denial of Care for Randomized Controlled Trial-Eligible Patients: Incidence and Success Rate of Peer-To-Peer Authorization in Allowing Patients to Remain Trial-Eligible. | Am J Clin Oncol | 2024 | https://conductscience.org/library/papers/37815344 | PubMed |
| 18 | 33956494 | An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. | Am Soc Clin Oncol Educ Book | 2021 | https://conductscience.org/library/papers/33956494 | PubMed |
| 19 | 36480773 | Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36480773 | PubMed |
| 20 | 32704619 | Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. | JNCI Cancer Spectr | 2020 | https://conductscience.org/library/papers/32704619 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42518232
GET https://conductscience.org/api/papers/v1/42518232/references?page=2